Emerging therapeutic targets for hepatitis C virus infection

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 6, 2013, Pages 612-619.e1

  Jesudian, Arun B ^a   de Jong, Ype P ^a,b   Jacobson, Ira M ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Boceprevir.; Direct Acting Antivirals; Hepatitis C; Interferon free Therapy; Telaprevir

Indexed keywords

ABT 333; ABT 450; ALISPORIVIR; ASUNAPREVIR; BI 207127; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; INTERLEUKIN 28B; ITX 5061; LEDIPASVIR; LOMIBUVIR; MERICITABINE; MIRAVIRSEN; NEUTRALIZING ANTIBODY; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; DISEASE SEVERITY; DRUG SAFETY; DRUG TARGETING; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; INSULIN RESISTANCE; LIVER FIBROSIS; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RACE; RASH; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

EID: 84878116699     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.04.003     Document Type: Article

References (66)

1. Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000, 20:1-16.
2. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
3. Lohmann V., Körner F., Koch J., et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
4. Lemon S.M., McKeating J.A., Pietschmann T., et al. Development of novel therapies for hepatitis C. Antiviral Res 2010, 86:79-92.
5. Wakita T., Pietschmann T., Kato T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11:791-796.
6. Lindenbach B.D., Evans M.J., Syder A.J., et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
7. Zeisel M.B., Felmlee D.J., Baumert T.F. Hepatitis C virus entry. Curr Top Microbiol Immunol 2013, 369:87-112.
8. Schoggins J.W., Rice C.M. Innate immune responses to hepatitis C virus. Curr Top Microbiol Immunol 2013, 369:219-242.
9. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119:1745-1754.
10. Kaiser J. Animal models. Advisers urge NIH to scale back chimpanzee research. Science 2013, 339:501.
11. Park S.H., Shin E.C., Capone S., et al. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology 2012, 143:1048-1060.
12. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
13. Swain M.G., Lai M.Y., Shiffman M.L., et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010, 139:1593-1601.
14. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
15. Reddy K.R., Shiffman M.L., Rodriguez-Torres M., et al. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology 2010, 139:1972-1983.
16. Romero-Gómez M., Del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
17. Martinot-Peignoux M., Marcellin P., Pouteau M., et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995, 22:1050-1056.
18. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
19. Simmonds P., Alberti A., Alter H.J., et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994, 19:1321-1324.
20. Dusheiko G., Schmilovitz-Weiss H., Brown D., et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994, 19:13-18.
21. Davis G.L., Lau J.Y. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997, 26(Suppl 1):122S-127S.
22. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
23. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
24. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
25. Incivek [package insert] 2012, Vertex Pharmaceuticals, Inc, Cambridge, MA.
26. Buti M., Agarwal K., Horsmans Y.J., et al. OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naive, genotype 1 HCV infected patients (abstr). Hepatology 2012, 56:1521A-1522A.
27. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
28. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
29. Victrelis [package insert] 2011, Merck & Co, Inc, Whitehouse Station, NJ.
30. Fried M., Buti M., Dore G.J., et al. TMC-435 in combination with peginterferon and ribavirin in treatment-naïve HCV genotype 1 patients: final analysis of the PILLAR phase study (abstr). Hepatology 2011, 54(Suppl):1429A.
31. Zeuzem S., Berg T., Gane E. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final SVR24 results of the ASPIRE trial (abstr). J Hepatol 2012, 56(Suppl 2):S1-S12.
32. Sulkowski M.S., Ceasu E., Asselah T., et al. SILEN-C1: sustained virologic response (SVR) and safety of BI1201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV infection (abstr). J Hepatol 2011, 54(Suppl 1):S27.
33. Sulkowski M.S., Bourliere M., Bronowicki J.-P., et al. SILEN-C2: sustained virologic response (SVR) and safety of BI1201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype 1 patients with non-response to P/R (abstr). J Hepatol 2011, 54(Suppl 1):S30.
34. Everson G.T., Cooper C., Hezode C., et al. High SVR24 rates with ritonavir-boosted danoprevir plus pegIFN alfa-2a (40KD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study (abstr). Hepatology 2012, 56(Suppl 4):552A.
35. Hezode C., Hirschfield G.M., Ghesquiere W., et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naïve HCV-genotype 1 or 4 subjects: phase 2b COMMAND study (abstr). Hepatology 2012, 56(Suppl 4):553A.
36. Lawitz E., Lalezari J.P., Hassanein T., et al. PROTON: PSI-7977 & Peg/RBV in treatment-naïve patients with HCV GT1: sustained virologic response (abstr). Hepatology 2011, 54(Suppl 1):474A.
37. Hassanein T., Lawitz E., Crespo I., et al. Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naive patients with HCV genotype 1, 4, and 6 infection in the ATOMIC study (abstr). Hepatology 2012, 56(Suppl 4):307A.
38. Jacobson I.M., Sulkowski M.S., Gane E.J., et al. VX-222, telaprevir, and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen (abstr). Hepatology 2012, 56(Suppl 4):308A.
39. Lok A.S., Gardiner D.F., Hezode C., et al. Sustained virologic response in chronic HCV genotype (GT)-1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV) (abstr). Hepatology 2012, 56(Suppl 4):230A.
40. Feld J.J., Jacobson I.M., Jensen D.M., et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB), and ribavirin (R) ± peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study (abstr). Hepatology 2012, 56(Suppl 4):231A-232A.
41. Zeuzem S., Arora S., Bacon B., et al. Pegylated interferon-lambda (PEGIFNλ) shows superior viral response with improved safety and tolerability versus PEGIFNα-2A in HCV patients (G1/2/3/4): EMERGE phase IIB through week 12 (abstr). J Hepatol 2011, 54(Suppl 1):S538-S539.
42. Gane E.J., Roberts S.K., Stedman C.A., et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010, 376:1467-1475.
43. Lok A.S., Gardiner D.F., Lawitz E., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012, 366:216-224.
44. Chayama K., Takahashi S., Toyota J., et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012, 55:742-748.
45. Gane E.J., Pockros P., Zeuzem S., et al. Interferon-free treatment with a combination of mericitabine and donoprevir/r with and without ribavirin in treatment-naïve HCV genotype-1 infected patients (abstr). J Hepatol 2012, 56(Suppl 2):S477-S478.
46. Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368:34-64.
47. (Press release). Gilead announces early sustained virologic response rates for GS-7977 plus ribavirin in genotype 1 treatment naive hepatitis C patients-Interim results reported from ELECTRON and QUANTUM studies, 2012 Gilead Sciences, Accessed: January 24, 2013. http://www.gilead.com/pr_1684792.
48. Osinusi A., Heytens L., Lee Y.J., et al. High efficacy of GS-7977 in combination with low or full dose ribavirin for 24 weeks in difficult to treat HCV infected genotype 1 patients. Hepatology 2012, 56(Suppl 4):230A.
49. Zeuzem S., Soriano V., Asselah T., et al. Interferon (IFN)-free combination treatment with the HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NS5B inhibitor BI 207127 ± ribavirin (R): final results of SOUND-C2 and predictors of response (abstr). Hepatology 2012, 56(Suppl 4):308A-309A.
50. Soriano V., Gane E., Angus P., et al. Efficacy and safety of the interferon (IFN)-free combination of BI 201335 + BI 207127 +/- ribavirin in treatment-naïve patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: results from the SOUND-C2 study (abstr). Hepatology 2012, 56(Suppl 4):234A.
51. Poordad F., Lawitz E., Kowdley K.V., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013, 368:45-53.
52. Kowdley K.V., Lawitz E., Poordad F., et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333, and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection (abstr). Hepatology 2012, 56:1515A-1516A.
53. Gane E.J., Stedman C.A., Hyland R.H., et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial (abstr). Hepatology 2012, 56(Suppl 4):306A-307A.
54. Sulkowski M., Gardiner D.F., Rodriguez-Torres M., et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCV genotype 1, 2, or 3 (abstr). Hepatology 2012, 56:1516A.
55. Cho N.J., Dvory-Sobol H., Lee C., et al. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Sci Transl Med 2010, 2. 15ra6.
56. Ciesek S., Steinmann E., Wedemeyer H., et al. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 2009, 50:1638-1645.
57. Liu Z., Yang F., Robotham J.M., et al. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol 2009, 83:6554-6565.
58. Verdegem D., Badillo A., Wieruszeski J.M., et al. Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A. J Biol Chem 2011, 286:20441-20454.
59. Flisiak R., Pawlotsky J.M., Crabbe R., et al. Once daily alisporivir (DEB025) plus Peg-IFN-αlfa-2A/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naïve patients-the ESSENTIAL study. J Hepatol 2011, 54:S2.
60. Nelson D.R., Ghalib R.H., Sulkowski M., et al. Efficacy and safety of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2A and ribavirin in previously null-responder genotype 1 HCV patients. J Hepatol 2009, 50:S40.
61. Pawlotsky J.M., Sarin S.K., Foster G.R., et al. Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study. Hepatology 2012, 56(Suppl 4):233.
62. Jopling C.L., Yi M., Lancaster A.M., et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005, 309:1577-1581.
63. Janssen H.L., Reesink H.W., Lawitz E.J., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, [Epub ahead of print].
64. Morin T.J., Broering T.J., Leav B.A., et al. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog 2012, 8:e1002895.
65. Meuleman P., Hesselgesser J., Paulson M., et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008, 48:1761-1768.
66. Meuleman P., Catanese M.T., Verhoye L., et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012, 55:364-372.